Results of therapy and changing prognosis of multiple myeloma during the last 40 years in the region of North and Middle Moravia: Group of 562 patients

Hematology Journal

Volumn 4, Issue 5, 2003, Pages 351-357

  Scudla, Vlastimil ^a   Bacovsky, Jaroslav ^a   Indrak, Karel ^a   Kodouskova, Vera ^a   Vytrasova, Marketa ^a   Faber, Edgar ^a   Papajik, Tomas ^a   Adam, Zdenek ^b   Hajek, Roman ^b   Horak, Pavel ^a   Martinek, Arnost ^c  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

Author keywords

Autologous stem cell transplantation; Conventional chemotherapy; High dose therapy; Multiple myeloma; Prognosis; Therapy results

Indexed keywords

ALPHA INTERFERON; ARSENIC TRIOXIDE; BISPHOSPHONIC ACID DERIVATIVE; CARMUSTINE; CLODRONIC ACID; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ESTRADIOL 3 METHYL ETHER; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; IMMUNOGLOBULIN; LOMUSTINE; MELPHALAN; METHYLPREDNISOLONE; MITOXANTRONE; PAMIDRONIC ACID; PREDNISONE; PROTEINASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; CZECH REPUBLIC; DATA ANALYSIS; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PROGNOSIS; RETROSPECTIVE STUDY; SEX RATIO; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CZECH REPUBLIC; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 12444338940     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200309     Document Type: Article

References (41)

1. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994; 330: 484-489.
2. Alexanian R, Dimopoulos MA. Management of multiple myeloma. Semin Hematol 1995; 21: 20-30.
3. Kyle RA. Long-term survival in multiple myeloma. N Engl J Med 1978; 19: 314-318.
4. Osgood E. The survival time of patients with plasmocytic myeloma. Cancer Chemother Rep 1960; 9: 1-10.
5. Alexanian R, Bergsagel DE, Migliore PJ, Vaughn WK, Howe CD. Melphalan therapy for plasma cell myeloma. Blood 1968; 31: 1-10.
6. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10: 334-342.
7. Hjorth M, Holmberg E, Rödjer S, Turesson I, Westin J, Wislöff F. Survival in conventionally treated younger (< 60 years) multiple myeloma patients: no improvement during two decades. Eur J Haematol 1999; 62: 217-277.
8. Oken M, Harrington D, Abramson N, Kyle RA, Knospe W, Glick JH. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide and prednisone in the treatment of multiple myeloma. Results of Eastern Cooperative Oncology Group study E 2479. Cancer 1997; 79: 1561-1567.
9. Peest D, Deicher H, Coldwey R, Schmoll HJ, Schedel I. Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP. Eur J Cancer Clin Oncol 1988; 24: 1061-1067.
10. Boccadoro M, Pileri A. Diagnosis, prognosis, and standard treatment of multiple myeloma. Hematol Oncol N Am 1997; 11: 111-131.
11. Dubost JJ, Ristori JM, Soubrier M, Zbadi K, Bussiere JL, Sauvezie B. Prognosis of multiple myeloma treated with conventional chemotherapy has not improved in 20 years. Rev Med Int 1996; 17: 895-900.
12. Myeloma Trialist's Collaborative Group: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomised trials. J Clin Oncol 1998; 16: 3832-3842.
13. Alexanian R, Dimopoulos M, Smith T, Delasalle K, Barlogie B, Champlin R. Limited value of myeloablative therapy for late multiple myeloma. Blood 1994; 83: 512-516.
14. Gahrton G, Björkstrand B. New treatment strategies in multiple myeloma. In: Education Sessions of the Second EHA. Blackwell Science Ltd: Paris, 1996, pp 17-19.
15. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
16. Attal M, Harousseau J-L, Stoppa AM, Sotto J-J, Fuzibet J-G, Rossi JF. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
17. Attal M, Harousseau J-L, Stoppa AM, Sotto JJ, Fuzibet G, Rossi JF et al. Autologous transplantation - clinical results in multiple myeloma. Blood 1997; 90: 418a.
18. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma up front or rescue treatment. Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131-3136.
19. Harousseau J-L, Attal M. The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin Hematol 1997; 34: 61-66.
20. Jagannath S, Tricot G, Barlogie B. Autotransplants in multiple myeloma: pushing the envelope. Hematol Oncol Clin N Am 1997; 11: 363-381.
21. Imrie K, Esmail R, Meyer RM. The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the cancer care Ontario practice guidelines initiative. Ann Intern Med 2002; 136: 619-629.
22. Lokhorst HM, Sonneveld P, Verdonck LF. Intensive treatment for multiple myeloma: where do we stand? Br J Haematol 1999; 106: 18-27.
23. Owen RG, Morgan GJ. Evolution of treatment strategies in multiple myeloma. Clin Lab Hematol 1998; 20: 199-206.
24. Rajkumar SV, Gertz MA, Kyle RA, Greipp PR. Current therapy for multiple myeloma. Mayo Clin Proc 2002; 77: 813-822.
25. Reece DE. New advances in multiple myeloma. Curr Opin Hematol 1998; 5: 460-464.
26. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842-854.
27. Boccadoro M, Palumbo A, Argentino Ch, Dominietto A, Frieri R, Avvisati G. Conventional induction treatments do not influence overall survival in multiple myeloma. Br J Haematol 1997; 96: 333-337.
28. San Miguel JF. Supportive therapy for complications in multiple myeloma. In: Education Sessions of the Second EHA. Blackwell Science Ltd: Paris, 1996, pp 12-16.
29. Krejci M, Hajek R, Scudla V, Bacovsky J, Indrak K, Faber E et al. Autologous transplantation of peripheral haematopoietic cells and subsequent maintenance therapy with interferon alpha or interpheron alpha and dexamethasone in patients with multiple myeloma - results of a Randomized Clinical 4W study of the Czech Myeloma Group. Vnitr Lek 2001; 47: 40-47.
30. Durie BGM, Russel DM, Salmon SE. Reappraisal of plateau phase in myeloma. Lancet 1980; 2: 65-68.
31. Hoogstraten B, Sheehe PR, Cuttner J, Cooper T, Kyle RA, Oberfield RA et al. Melphalan in multiple myeloma. Blood 1967; 30: 74-83.
32. Oivanen TM, Kellokumpu-Yettinen P, Koivisto A-M, Koivunen E, Palva I. Response level and survival after conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study. Eur J Haematol 1999; 62: 109-116.
33. Finnish Leukaemia Group. Long-term survival in multiple myeloma: a Finnish Leukaemia Group study. Br J Haematol 1999; 105: 942-947.
34. Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson M, Hickish T et al. High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12: 759-763.
35. Björkstrand B, Svensson H, Ljungman P, Apperley J, Goldschmidt H, Remes K et al. 2522 autotransplants in multiple myeloma: a registry study from the European Group for Blood and Marrow Transplantation (EBMT). Blood 1997; 90: 419a.
36. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen L. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 2000; 95: 7-11.
37. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LLM, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantations. Blood 1997; 90: 4206-4211.
38. Barlogie B, Jagannath S, Desikan KR, Mattox W, Vesole D, Siegel D. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
39. Blade J, San Miguel JF, Fontanillas M, Alcala A, Maldonado J, Garcia-Conde J et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated. J Clin Oncol 1996; 14: 2167-2173.
40. Anderson K. Advances in the biology of multiple myeloma: therapeutic applications. Semin Oncol 1999; 26: 10-20.
41. Davies FE, Anderson KC. Novel therapeutic targets in multiple myeloma. Eur J Haematol 2000; 64: 359-367.